-
HEOR Theater - Addressing Prenatal Exposures and Outcomes for Regulatory Requirements Using Real-World Data
1:00PM - 1:45PM EST
-
HEOR Theater - Effect Modification in Network Meta-Analysis: Is Population Adjustment Always the Answer?
12:00PM - 12:45PM EST
-
HEOR Theater - Optimizing Research Using Real-World Data During the COVID-19 Pandemic
11:00AM - 11:45AM EST
-
Signal - Episode 5- On-demand until November 30
Join Tom Cassels and Alyssa Jaffe - seasoned venture capital investors with background from the healthcare settings - in discussing the highlights, possible implications and learnings from investment activity for the downstream healthcare decision-making where stakeholders are looking primarily at evidence-based solutions.
-
Evolving Real World Data/Evidence Guidelines and Landscape in China: From Policy to Practice
-
6-7 October: Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element.
-
Health Preference Research in the Context of Gene Therapy in Rare Diseases
-
27-28 September: Causal Inference and Causal Diagrams in Big, Real-World Observational Data and Pragmatic Trials
There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes involve a plan by which the performance of the product is tracked in a defined patient population over a specified period of time and the level of reimbursement is tied by formula to the outcomes achieved.
-
HEOR Theater - Using Item Banks to Build Condition Specific Static Short Form Outcome Measures
1:00PM - 1:45PM EST
-
HEOR Theater - Health Technology Assessment in 2030: How Methods, Technology and Data will Change the Way Drugs are Reimbursed
12:00PM - 12:45PM EST
-
HEOR Theater - Making the most of the NICE methods updates to optimize evidence generation and global HTA strategy
10:00AM - 10:45AM EST
-
Embedded Clinical Trials: Understanding the Opportunities and Challenges for Real-World Evidence Generation
11:00AM - 12:00PM EST
-
Innovations in Value Communication: Optimizing Payer Engagement at the Local Level
11:00AM - 12:00PM EST
-
31 August: Developing Decision-Grade Real-World Evidence
In this course, participants will be guided through a hands-on analysis of real-world data (RWD) to develop decision-grade real-world evidence (RWE) that could be used to support an indication expansion.
-
ISPOR Educational Webinar: The Health Preference Research Landscape - Preference Information, Methods, and Use
-
Use of External Controls for Oncology RWE Studies to Enhance Development and Accelerate Knowledge of New Treatments
-
11-12 August: Applied Cost-Effectiveness Modeling with R
This course is designed to teach clinicians and new researchers how to incorporate health economics into study design and data analysis.
-
2-5 August: Introduction to Health Economics and Outcomes Research
This course is designed to teach clinicians and new researchers how to incorporate health economics into study design and data analysis.
-
27-28 July: Advanced Decision Modeling for Health Economic Evaluations
During this course, the key aspects and new developments of decision modeling for economic analysis will be considered. How models can be made probabilistic to capture parameter uncertainty (including rationale, choosing parameter distributions, and types of uncertainty) will be covered.
-
Signal - Episode 3
Join us virtually on July 15 at the third Signal Series event to engage with NICE—The National Institute for Health and Care Excellence, United Kingdom, as the NICE leaders discuss the Institute’s plans to remain at the forefront of anticipating and rapidly evaluating existing and new technologies including digital health technologies, driving future research agenda and developing leading capabilities for routine use of real world evidence.